1. Home >
  2. M&A >
  3. Stake Purchase >
  4. India >
  5. Cipla Invests In Achira

Investment Summary

Cipla Invests In Achira

On June 17, 2022, Cipla invested in medical products company Achira

Investment Highlights
  • This is Cipla’s 1st transaction in the Medical Products sector.
  • This is Cipla’s 1st transaction in India.

Investment Summary
Date 2022-06-17
Target Achira
Sector Medical Products
Investor(s) Cipla
Deal Type Stake Purchase

Target

Achira

Bengaluru, India
Achira is an associate company engaged in development and commercialization of point-of-care (PoC) medical test kits in India. The company develops regulatory-approved medical diagnostic products using microfluidic technology. Achira is based in Bengaluru, India.

Search 205,615 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Cipla

Mumbai, India
Category Company
Founded 1935
Sector Life Science
Employees25,672
Revenue 254.5B INR (2024)
DESCRIPTION

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. Cipla was founded in 1935 and is based in Mumbai, India.

DEAL STATS #
Overall 6 of 6
Sector (Medical Products) 1 of 1
Type (Stake Purchase) 1 of 1
Country (India) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-24 ZEMDRI

San Francisco, California, United States

ZEMDRI (Plazomicin) is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options. ZEMDRI™ was approved by the United States Food & Drug Administration (USFDA) in June 2018 and was launched in the same year, with patent protection expected to continue until 2031 or 2032.

Buy -
Mergr

Product

Company

Legal